A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration

Mukhopadhyay, Gauranga; Doherty, Patrick; Walsh, Frank S.; Crocker, Paul R.; Filbin, Marie T.

doi:10.1016/0896-6273(94)90042-6

Cited by 978 publications

(653 citation statements)

References 52 publications

Supporting

Mentioning

634

Contrasting

Unclassified

Order By: Relevance

“…Myelin-associated glycoprotein was the first myelin inhibitor to be identified (Mukhopadhyay et al, 1994;McKerracher et al, 1994). Myelin-associated glycoprotein is a member of the immunoglobulin (Ig)-like family (Salzer et al, 1987(Salzer et al, , 1990.…”

Section: Myelin-associated Glycoproteinmentioning

confidence: 99%

Myelin—Associated Inhibitory Signaling and Strategies to Overcome Inhibition

Chaudhry

Filbin

2006

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

Numerous studies in the last two decades have resulted in significant progress in our understanding of the role of inhibitors on axonal regeneration and conditions that influence mature neurons to regrow in an inhibitory environment. These studies have revealed putative therapeutic targets and strategies to interfere in the inhibitory signaling cascade and promote axonal regeneration. Some agents that were successful in animal models are now being tested in human patients. All of these advances have raised hope of a cure for an injury that was once thought to be 'an ailment for which nothing is done' (Quote from Edwin Smith surgical papyrus, 1600BC).

show abstract

Section: Myelin-associated Glycoproteinmentioning

confidence: 99%

Myelin—Associated Inhibitory Signaling and Strategies to Overcome Inhibition

Chaudhry

Filbin

2006

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

show abstract

“…In fact, Nogo -now known to exist in three isoforms 35,36 -is but one of a number of myelin-derived inhibitory proteins. Others identified thus far include myelinassociated glycoprotein (MAG) 37,38 and oligodendrocyte myelin glycoprotein (OMgp). 39 The role of MAG as an impediment to axonal regeneration is exemplified by in vitro studies in which its immunodepletion from myelin extracts attenuated inhibitory activity.…”

Section: Myelin and Myelin Signaling: An Inhibitory Chorus Linementioning

confidence: 99%

Setting the stage for functional repair of spinal cord injuries: a cast of thousands

2005

View full text Add to dashboard Cite

Here we review mechanisms and molecules that necessitate protection and oppose axonal growth in the injured spinal cord, representing not only a cast of villains but also a company of therapeutic targets, many of which have yet to be fully exploited. We next discuss recent progress in the fields of bridging, overcoming conduction block and rehabilitation after spinal cord injury (SCI), where several treatments in each category have entered the spotlight, and some are being tested clinically. Finally, studies that combine treatments targeting different aspects of SCI are reviewed. Although experiments applying some treatments in combination have been completed, auditions for each part in the much-sought combination therapy are ongoing, and performers must demonstrate robust anatomical regeneration and/or significant return of function in animal models before being considered for a lead role.Spinal Cord (2005) 43, 134-161.

show abstract

“…16 Many experiments, described in more detail later, have shown that blocking NogoA with the blocking antibody IN-1 can promote regeneration and sprouting of axons in the spinal cord and other parts of the CNS. 17 Other inhibitory molecules produced by myelin are myelinassociated glycoprotein (MAG) 18 and the chondroitin sulphate proteoglycan (CSPG) versican. 19 These molecules are all present in normal myelin, but are probably released in larger amounts when myelin is disrupted in injuries.…”

Section: Why Do Axons Fail To Regenerate In the Spinal Cord?mentioning

confidence: 99%

Repair of spinal cord injuries: where are we, where are we going?

Fawcett

2002

Spinal Cord

View full text Add to dashboard Cite

Repairing the spinal cord has for a long time been a`holy grail' for neuroscientists. No achievement in neuroscience is more di cult to achieve, and none would have the same impact amongst the medical profession and the public. Yet no patient has yet bene®ted from a regeneration therapy. At last su cient progress has been made in the basic science of axon regeneration that treatments that would partially repair a spinal injury are imminent. A full repair of spinal injury still remains elusive. This review summarises progress to date, and suggests ways in which progress towards treatment of spinal injury patients might be made.

show abstract

A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration

Cited by 978 publications

References 52 publications

Myelin—Associated Inhibitory Signaling and Strategies to Overcome Inhibition

Myelin—Associated Inhibitory Signaling and Strategies to Overcome Inhibition

Setting the stage for functional repair of spinal cord injuries: a cast of thousands

Repair of spinal cord injuries: where are we, where are we going?

Contact Info

Product

Resources

About